MRNA close to buyI think 20$ is a good support to buy MRNA. It gave 100% of the covid gains back.
Base - Rally - Base pattern
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−9.28 USD
−3.56 B USD
3.24 B USD
341.66 M
About Moderna, Inc.
Sector
Industry
CEO
Stéphane Bancel
Website
Headquarters
Cambridge
Founded
2010
FIGI
BBG003PHHZT1
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Moderna (MRNA) Shares Plunge Nearly 9%Moderna (MRNA) Shares Plunge Nearly 9%
Moderna (MRNA) shares tumbled by approximately 8.9%, falling below $29—marking their lowest level since April 2020, when global markets were shaken by the COVID-19 pandemic.
Since the start of 2025, MRNA’s share price has declined by around 32%.
Why Did MR
Moderna. Why Anti-Covid19 Juggernaut Goes 'The Bloodmachine'It's gone 5 years or so... (Duh..? 5 years, really? 🥴) since everyone was talking about COVID-19 pandemic, vaccines, "world will never be the same again", and so on.
- And now?..
- It's gone. It's absolutely gone..! Since nothing last forever and no one should chase a feather, or dust in the wind.
$MRNA: Moderna – mRNA Magic or Biotech Bubble?(1/9)
Good afternoon, folks! ☀️ NASDAQ:MRNA : Moderna – mRNA Magic or Biotech Bubble?
CEO drops $5M on shares, sparking a 9% surge—is this a biotech rocket or a hot air balloon ready to pop? Let’s crack the code! 🔍
(2/9) – PRICE PERFORMANCE 📊
• Current Trend: Up 9% after CEO’s $5M buy on Mar 5,
MRNA'Ticker: MRNA
Direction: Up
Prognosis: Buy Calls (Author bought $40 and $41 calls expiring this week, considering rolling to later dates)
Reasoning: New Covid-like virus discovered, rising avian flu concerns, large institutional buying, bullish technical indicators (RSI divergence, MACD turning u
MRNA SL-$30,95 TP-$33Technical Analysis:
Weakness in bearish candles
Increase in volume may indicate a reversal
Engulfing candle on the daily chart
A reversal towards the mean on the H4 chart is likely
MACD on H4 indicates a probable inflection point
Strength on MRNADespite negative news, Moderna, Inc. stock is in a good position to rally. Its price has been falling since August 2021, but relatively big buys have begun to emerge since August 2024.
It has to be noted that on every bar with buying, volume is increasing, which is usually a sign of accumulation on
Moderna Faces Another Quarterly Loss, Yet Shares Show ResilienceModerna Inc. (NASDAQ: NASDAQ:MRNA ) has once again reported a quarterly loss, reflecting the continued decline in COVID-19 vaccine sales and an unexpected charge related to a canceled manufacturing contract. Despite this, shares of the biotech giant saw a 3.35% uptick, signaling a mixed sentiment a
MRNA Moderna Options Ahead of EarningsIf you haven`t bought MRNA before the previous earnings:
Now analyzing the options chain and the chart patterns of MRNA Moderna prior to the earnings report this week,
I would consider purchasing the 45usd strike price Calls with
an expiration date of 2025-9-19,
for a premium of approximately $3.
$MRNA yieahhhrough day for some, good day for my DCA friends.
NASDAQ:MRNA on a rough down trend since covid days. Looking for a wild bounce here.
1. MACD curving to the upside
2. RSI Curving to the upside
3. Price is at the bottom of the parallel channel.
My bets are on seeing $60-$70 which is middle of th
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where MRNA is featured.
Related stocks
Frequently Asked Questions
The current price of MRNA is 25.74 USD — it has increased by 2.43% in the past 24 hours. Watch Moderna, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Moderna, Inc. stocks are traded under the ticker MRNA.
MRNA stock has fallen by −4.03% compared to the previous week, the month change is a −19.69% fall, over the last year Moderna, Inc. has showed a −74.96% decrease.
We've gathered analysts' opinions on Moderna, Inc. future price: according to them, MRNA price has a max estimate of 212.00 USD and a min estimate of 20.00 USD. Watch MRNA chart and read a more detailed Moderna, Inc. stock forecast: see what analysts think of Moderna, Inc. and suggest that you do with its stocks.
MRNA reached its all-time high on Aug 10, 2021 with the price of 497.49 USD, and its all-time low was 11.54 USD and was reached on Aug 7, 2019. View more price dynamics on MRNA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
MRNA stock is 3.90% volatile and has beta coefficient of 0.99. Track Moderna, Inc. stock price on the chart and check out the list of the most volatile stocks — is Moderna, Inc. there?
Today Moderna, Inc. has the market capitalization of 9.93 B, it has decreased by −1.61% over the last week.
Yes, you can track Moderna, Inc. financials in yearly and quarterly reports right on TradingView.
Moderna, Inc. is going to release the next earnings report on May 1, 2025. Keep track of upcoming events with our Earnings Calendar.
MRNA earnings for the last quarter are −2.91 USD per share, whereas the estimation was −2.68 USD resulting in a −8.57% surprise. The estimated earnings for the next quarter are −3.11 USD per share. See more details about Moderna, Inc. earnings.
Moderna, Inc. revenue for the last quarter amounts to 966.00 M USD, despite the estimated figure of 942.82 M USD. In the next quarter, revenue is expected to reach 118.40 M USD.
MRNA net income for the last quarter is −1.12 B USD, while the quarter before that showed 13.00 M USD of net income which accounts for −8.72 K% change. Track more Moderna, Inc. financial stats to get the full picture.
No, MRNA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 23, 2025, the company has 5.8 K employees. See our rating of the largest employees — is Moderna, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Moderna, Inc. EBITDA is −3.76 B USD, and current EBITDA margin is −116.07%. See more stats in Moderna, Inc. financial statements.
Like other stocks, MRNA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Moderna, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Moderna, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Moderna, Inc. stock shows the sell signal. See more of Moderna, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.